Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,422 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05284591 | Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)(MYLENE) | completed | — | 96 | iOMEDICO AGINDUSTRY |
| 1 |
| Oct 1, 2024 |
| clinicaltrials |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | completed | Phase 1 | 4 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02939183 | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma(INTREPID-1) | completed | Phase 1 | 61 | AmgenINDUSTRY | 4 | Sep 26, 2024 | clinicaltrials |
| NCT05101759 | Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy(LYMPHOLD) | completed | N/A | 100 | University Hospital, ToulouseOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02892383 | Quality of Life the Danish Multiple Myeloma Patients(QoL-MM) | completed | — | 681 | Odense University HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06160167 | Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | completed | — | 4,204 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03829020 | Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT04760405 | The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | completed | N/A | 12 | University of ArizonaOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06552221 | Finistere Myeloma Observatory (OMYFIN)(OMYFIN) | completed | — | 300 | University Hospital, BrestOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03119883 | Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma | completed | N/A | 35 | Mayo ClinicOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04217967 | Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | completed | Phase 4 | 211 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02148913 | Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma | completed | Phase 1 | 18 | Corewell Health WestOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04394650 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 78 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT04840680 | A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) | completed | — | 191 | TakedaINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT00551928 | Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients(MPRvsMEL200) | completed | Phase 3 | 402 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02215980 | STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS | completed | Phase 3 | 210 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | completed | Phase 2 | 61 | TakedaINDUSTRY | 6 | Jul 3, 2024 | clinicaltrials |
| NCT03952091 | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 289 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Jul 3, 2024 | clinicaltrials |
| NCT04434469 | A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 27 | Genentech, Inc.INDUSTRY | 4 | Jul 3, 2024 | clinicaltrials |
| NCT05679258 | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects | completed | Phase 1 | 172 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04379817 | Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients(SCARLET) | completed | Phase 2 | 23 | Jules Bordet InstituteOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT05882279 | A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan | completed | — | 330 | TakedaINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT01283997 | Prevention of Treatment Induced Neuropathy in Multiple Myeloma | completed | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03309111 | Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 81 | Ichnos Sciences SAINDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | completed | Phase 1 | 70 | Sutro Biopharma, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03234972 | A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 2 | May 29, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03143985 | Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 18 | Koen van BesienOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03430011 | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma(EVOLVE) | completed | Phase 1 / Phase 2 | 165 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT05064787 | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | completed | N/A | 45 | Pack HealthINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT03184194 | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide | completed | Phase 2 | 62 | Amsterdam UMC, location VUmcOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05565391 | A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | completed | — | 508 | PfizerINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT02101944 | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | May 17, 2024 | clinicaltrials |
| NCT02697383 | Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study | completed | Phase 1 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 1, 2024source: clinicaltrials